Skip to main content
Clinical Trials/EUCTR2010-021412-42-GB
EUCTR2010-021412-42-GB
Active, not recruiting
Phase 1

Prospective randomised controlled trial to investigate the effectiveness of inhalers for the relief of breathlessness in patients with lung cancer and COPD - Airway disease optimisation of pharmaco-therapy in lung cancer

Royal Marsden Hospital0 sites65 target enrollmentOctober 8, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Chronic obstructive pulmonary disease, lung cancer
Sponsor
Royal Marsden Hospital
Enrollment
65
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 8, 2010
End Date
July 14, 2016
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Royal Marsden Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\.Male or female, age \> 35 years
  • 2\.Diagnosis of lung cancer ( Non\-small cell lung cancer, Small cell lung cancer and mesothelioma)
  • 3\.Diagnosis of chronic obstructive pulmonary disease (COPD)
  • 4\.Subjective dyspnoea (breathlessness) of VAS score \>/\= 4
  • Are the trial subjects under 18?
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years)
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\.Involvement in any other studies of breathlessness
  • 2\.Reversible causes of breathlessness
  • 3\.Patients receiving radiotherapy, chemotherapy, biological therapy or surgery. Or with a plan to commence these treatments within 4 weeks
  • 4\.Current use of bronchodilators either inhaled or oral (aminophyline, methyxanthines) except for short\-acting bronchodilators
  • 5\.Recent change to oral corticosteroid therapy dose (within 1 week of randomisation)
  • 6\.Current use of beta\-blockers for any reason
  • 7\.Current use of anti\-cholinergic containing drugs
  • 8\.Current use of potent CYP30 inhibitors (ritonavir, ketoconazole, itraconazole)
  • 9\.Patients with the following conditions: asthma, severe cardiovascular disorders (myocardial infarction within 6 week), heart rhythm abnormalities, thyrotoxicosis, uncorrected hypokalaemia, glaucoma, prostate problems, patients with difficulty passing urine, renal failure, TB (current or previous)
  • 10\.Pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials